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ABSTRACT
Background. Surgical resection is the only curative
modality for colorectal liver metastases (CLM), and the
pattern of recurrences after resection affects survival. In a
prospective study of liver transplantation (Lt) for nonre-
sectable CLM we have shown a 5-year overall survival rate
of 60 %, but 19 of 21 experienced recurrence. This study
reports the pattern of recurrences after Lt for CLM and the
effect on survival.
Methods. Characterization of metastatic lesions in a pro-
spective study for Lt for nonresectable CLM was
performed (n = 21). The study included reexamination of
chest computed tomographic scans taken before Lt.
Results. At the time of first recurrence, 16 were a single
site, and three were multiple sites. Thirteen of the single
sites were pulmonary recurrences. The pulmonary recur-
rences appeared early and were slow growing, and several
were accessible to surgical treatment. When chest com-
puted tomographic scans were reexamined, seven patients
had pulmonary nodules at the time of Lt without an effect
on survival. There was no first single-site hepatic recur-
rence. Six of the seven patients who developed metastases
to the transplanted liver died from metastatic disease.
Conclusions. The pulmonary recurrences after Lt for
CLM were of an indolent character, even those that were
present at the time of Lt. This contrasts with the finding of
metastases to the transplanted liver, which was prognosti-
cally adverse. The lack of single hepatic first-site
recurrences and hepatic metastases only as part of dis-
seminated disease is different from the pattern of
recurrence after liver resection. This suggests two distinct
mechanisms for hepatic recurrences after resection for
CLM.
Chemotherapy as the sole treatment of colorectal liver
metastases (CLM) is palliative only, and the 5-year overall
survival (OS) after the start of first-line chemotherapy is
approximately 10 %.1 Surgical treatment of CLM is poten-
tially curative, and the median 5-year OS is 38 %, ranging
from 16 to 74 %.2 Recurrence after liver resection for CLM
happens in 60–70 % of the patients.3–5 The first site of
recurrence is most frequently liver only (28–45 %), fol-
lowed by lung only (17–27 %), multiple sites (28–30 %),
and locoregional or other single sites (9–12 %).3,4,6–8
Recently there have been several reports on the effect of the
pattern of the first site of recurrence on outcome after liver
resection for CLM. Not surprisingly, the survival is better for
single-site recurrences than for multiple sites.6,9 In a recent
report from Memorial Sloan-Kettering Cancer Center
(MSKCC), the best outcome after single-site lung metasta-
ses was demonstrated, and survival after single-site hepatic
recurrences was placed in between that after pulmonary and
multiple-site recurrences.6 Other reports show no difference
in survival between lung and liver recurrences.7,9
CLM is currently regarded as a contraindication for liver
transplantation (Lt). However, in a prospective study on Lt
for nonresectable CLM (n = 21), we showed a 5-year OS
of 60 % (95 % confidence interval, 34–85 %).10 Nineteen
of the 21 patients experienced recurrence of disease. A
significant proportion of the recurrences were accessible
for surgery, and at last follow-up, 33 % of the patients had
no evidence of disease.10
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The primary aim of the present study was to describe the
pattern of recurrences after Lt for CLM and to explore the
effect of these patterns on survival. Patterns of recurrence
after Lt for CLM have, to our knowledge, never been
described before. Also, complete removal of the affected
liver may give novel information about the biology of
metastatic spread, because it excludes the mechanism of
relapse caused by residual tumor cells situated in the liver.
Because of frequent pulmonary relapses, another aim of the
study was to reassess chest computed tomographic (CT)
scans on patients with pulmonary recurrence, to pinpoint
the timing of appearance.
METHODS
Patient Selection
A total of 21 patients with nonresectable CLM under-
went Lt in an open prospective pilot study; main inclusion
criteria were nonresectable CLM without signs of extrahe-
patic disease and a minimum of 6 weeks of
chemotherapy.10 The absence of extrahepatic disease was
assessed by chest, abdominal, and pelvic CT scans and
whole-body positron emission tomography/CT scan. The
examinations as part of the pretransplantation procedure
were done at various referring hospitals or at the trans-
plantation center as part of their routine diagnostic work.
CT scans taken at other hospitals were reexamined at our
department of radiology. The thicknesses of slices were
2.5–3 mm. If no sign of extrahepatic malignancy was
found, the patient was put on a waiting list for Lt. At
admission for Lt, a repeat chest CT scan was performed and
assessed by the radiologist on call at the transplantation
center. All of these were described as negative regarding
pulmonary metastasis. A staging laparotomy was performed
at the time of Lt. All chest CT scans taken before Lt and
during follow-up were retrospectively reassessed by an
experienced radiologist (T.S.E.) as part of the present study.
The immunosuppression protocol consisted of sirolimus,
mycophenolate mofetil, corticosteroids, and induction with
basiliximab. Sirolimus was introduced on the first postop-
erative day, aiming for a trough level of 5–10 ng/ml during
the first 4 weeks and 10–20 ng/ml thereafter. Corticoste-
roids were tapered to 0 or 5 mg daily at 1–2 months after
Lt. No adjuvant chemotherapy was given.
After discharge, chest, abdominal, and pelvic CT scans
were performed every 3 months for the first year and
thereafter every 6 months according to study protocol.
Patients with relapse of malignant disease were treated
individually.
The study was approved by the ethical and institutional
review board (S-05409 Regional Ethics Committee).
Statistical Analysis
Data were continuously registered in case report forms.
Survival data were estimated by using the Kaplan–Meier
method. Log-rank tests were used to compare survival
between subgroups. For all tests, a two-sided p \ 0.05 was
considered statistically significant. Analyses were per-
formed with SigmaPlot for Windows Version 11.0.
RESULTS
Diagnosis of Recurrence
Time to recurrence was defined as time to metastasis or
recurrence of the primary cancer during the follow-up
period. All hepatic recurrences were diagnosed by the
characteristic appearance of new lesions in the transplanted
liver on CT scans and/or ultrasound. In one patient,
resection of the metastatic lesion in the transplanted liver
was performed, and histology of the lesion showed ade-
nocarcinoma. In another patient, fine-needle aspiration
cytology of the lesion verified the diagnosis of metastases
from colorectal adenocarcinoma. In two other patients,
stereotactic radiation toward the liver was performed. In
one of these patients there was a transient decrease in
carcinoembryonic antigen from 112 to 49 lg/l.
For pulmonary relapses, the time to recurrence was
defined as when the pulmonary deposit was first described
as certain metastases on chest CT scans. In one case, the
hepatic recurrence was diagnosed on an additional
abdominal CT scan taken on clinical indications 40 days
before planned chest CT follow-up. This examination also
revealed pulmonary recurrence in the lower part of the
lungs. Accordingly, this patient was registered as having
simultaneous liver and lung relapse. The relapses were
diagnosed by CT examinations in 17 cases, the recurrent
rectal cancers were identified by magnetic resonance
examination, and one of the lymph node metastases was
diagnosed by positron emission tomography/CT scan.
Patients, Extent of Cancer Disease, and Treatment
The baseline demographics and clinical outcome of the
21 patients who underwent transplantation in the pilot
study were described previously.10 Briefly, the median time
of follow-up was 27 months (range, 8–60 months). The
Kaplan-Meier estimate for OS was 95, 68, and 60 % at 1,
3, and 5 years, respectively. The Kaplan–Meier estimate
for disease-free survival was 35 and 0 % at 1 and 3 years,
respectively. Two grafts were lost because of hepatic artery
thrombosis, and the patients underwent retransplantation at
4 and 12 days after first Lt.
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The inclusion criteria were quite wide regarding the
characteristics of the primary or hepatic tumor, previous
treatment, and response to chemotherapy. No limits were
given to characteristics such as carcinoembryonic antigen
levels, synchronous disease, or extent of hepatic tumor
load. Accordingly, the study population was heterogeneous
regarding characteristics of colorectal cancer disease and
previous treatments. Fourteen of the 21 patients had pro-
gressive disease on chemotherapy at the time of Lt, and
these patients had inferior survival.10 The metastatic tumor
load in the liver was extensive (Table 1).
Pattern of Recurrence
A total of 19 of the 21 patients developed recurrences.
All patients observed for more than 11 months experienced
recurrence of disease. The median time to recurrence was
6 months (range 2–24 months). At the end of follow-up,
seven patients were alive with no evidence of disease, eight
patients were alive with recurrence, and six patients were
deceased. The observational time for patients with no
evidence of disease was a median of 11 months (range,
6.5–25 months) since transplantation or last resection.
Time from diagnosis of recurrence to surgical treatment
was 7.9 months (range 0–21 months) in five patients. No
patient died of causes other than relapse of the malignant
disease.
The initial recurrence patterns were distributed as shown
in Fig. 1a: 68 % lung metastases, 11 % liver and lung
metastases, 11 % lymph node metastases, and 5 % liver
and ovarian metastasis. Five percent experienced local
recurrence of a rectal tumor as the first recurrence. No
patient had liver-only metastasis as the first site. The
median time from Lt to initial recurrence was 4 months
(range 2–24 months) for lung only, 6 months (range
2–15 months) for multiple site recurrences, and 12 months
(range 5–14 months) for other single-site recurrences.
Sixty-two percent of the patients with single-site lung
metastasis experienced recurrence of disease within the
first year.
The lung was the first single site of recurrence in 13
patients (Fig. 1b). Seven of these patients did not develop
other metastatic deposits, and three of these seven
underwent pulmonary resections. At the end of follow-up,
all seven patients were alive, two of them with no evi-
dence of disease at 9.5 and 25.0 months after resection. In
this group, one patient had a solitary very slowly growing
pulmonary tumor which had been observed for 23 months
without reaching 1 cm in diameter. Four of the patients
with lung as the first site of recurrence experienced other
locations as second sites; two patients had port-site
metastases to the costae after thoracoscopic pulmonary
resection, one patient was later diagnosed with a new
primary colon cancer, and one patient had ovarian
metastasis. The new primary colon cancer was resected,
and the patient had no evidence of disease 13.1 months
after pulmonary resection at the end of follow-up. In two
cases, the liver was the second site of tumor recurrence,
and one of the patients with port-site metastasis to the
costae experienced liver as the third metastatic site
30 months after Lt. All three patients died from metastatic
disease.
There were three single-site recurrences other than
pulmonary after Lt. One was a recurrent rectal cancer, and
two patients experienced metastases to paraaortal lymph
nodes. The patient with local relapse of rectal cancer
received chemoradiation and subsequent surgery of the
rectal relapse, and this patient had no evidence of disease
18.4 months after surgery at the end of follow-up. One of
the patients with lymph node metastasis developed liver
metastasis as a second-site recurrence and died. The other
underwent resection, received postoperative radiation
(50 Gy), and had no evidence of disease 6.4 months after
radiation treatment at the end of follow-up (Fig. 1b).
Three patients had recurrences at two sites simulta-
neously. The liver was involved in all three. Two of these
patients died at 6 and 26 months after Lt. One was alive
with disease after an ovarian resection for metastasis, but
with metastases in the liver and lungs.
TABLE 1 Baseline characteristics for patients undergoing liver
transplantation for nonresectable colorectal liver metastases
Characteristic Value
Age at treatment, years, median (range) 56 (45–65)
Sex, n (%)
Male 13 (62 %)
Female 8 (38 %)
Cancer treatment before transplantation, n (%)
Liver resection/RFA 6 (28 %)
Chemotherapy
Lines of chemotherapy received before Lt, n (%)
1 line 9 (43 %)
2 or 3 lines 12 (57 %)
Progression on chemotherapy at Lt, n (%) 14 (66 %)
Tumor characteristics, liver metastases
Number of metastases, median (range)a 8 (4–40)
Diameter of largest metastasis, cm, median (range)a 4.5 (2.8–13.0)
Carcinoembryonic antigen levels at time of Lt,
median (range)
15 (1–2002)
Lt liver transplantation, RFA radiofrequency ablation
a Largest number/diameter measured at CT scans before Lt or
examination of explanted liver
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Survival after Site of Recurrence
Patients with a pulmonary first-site recurrence had a
5-year survival of 72 % (95 % confidence interval
44–99 %; Fig. 2a) from the time of Lt. The 16 patients who
had single-site recurrences, both lung and other, had
significantly better survival than the three with multiple-
site recurrences, of whom all had liver metastases
(p = 0.013; Fig. 2b)
Seven patients developed hepatic metastases. The
median time from Lt to liver metastases was 6 months
(range 2–30 months). One of these patients underwent
Liver only: 0
Other: 0
Recurrence of primary tumor: 1 (5%)
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FIG. 1 a Distribution of first-site recurrences after liver transplan-
tation (Lt) for colorectal cancer for nonresectable liver metastases.
Nineteen patients had experienced recurrence at the end of follow-up.
b Surgical interventions and outcome according to distribution of first
and second site of recurrence after Lt. Of the 21 patients included in
study, six were dead, all because of disseminated cancer disease;
seven were with no evidence of disease (NED); and the remaining
eight were alive with disease (AWD). No patient was lost to follow-
up
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hepatic resection, two received stereotactic radiation
toward the liver, and subsequently one of these two patients
underwent transcatheter arterial chemoembolization treat-
ment. At the end of follow-up, six of these seven patients
were dead. The median time from diagnosis of liver
metastases to death was 14 months (range 4–21 months;
Figs. 2c, 3). In contrast, all 12 patients with recurrences
that did not include the liver were alive at the end of fol-
low-up. Patients with pulmonary metastases and no liver
metastases (ten patients) had a significantly better survival
from the time of relapse compared with patients diagnosed
with hepatic recurrence (p \ 0.001; Fig. 2c). The 5-year
OS after the diagnosis of recurrence was 57 % (Fig. 2d).
Tracing back from evident metastases on CT scans,
seven patients had pulmonary metastases at time of Lt.
Four of them had metastases 2–12 months before Lt. The
presence of metastases at the time of Lt did not have a
negative effect on survival. Only one of these patients died
during follow-up, and six of them were among the ones
with the longest survival in the study (Fig. 3). In some
cases, CT scans showed nodules with the same size and
appearance as the future evident metastases, but without
further growth, they were retrospectively considered
benign.
DISCUSSION
Seven of 21 patients experienced hepatic metastases after
Lt. The finding of hepatic recurrences of colorectal cancer in
a transplanted liver has, to our knowledge, not been
described previously. All patients in the study had excised
primary tumor, and all patients had undergone strict pre-
operative screening with CT and positron emission
tomography/CT scans and colonoscopy. No single-site
hepatic first recurrence was observed in the present study.
This contrasts with what is seen after liver resection for
CLM, where the proportion of hepatic first-site recurrences
is high (31–45 %).4,6,7 In a study of patients who underwent
First single site
First multiple sites
n = 19, P = 0.013
Pulmonary first site
n = 13
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FIG. 2 Nineteen of 21 patients
who experienced relapse after
liver transplantation for
colorectal liver metastasis were
assessed. All deaths were due to
disseminated cancer disease.
a Thirteen patients had
pulmonary-first metastases, and
the 5-year survival from the
time of Lt was 72 % (95 %
confidence interval 44–99 %).
b Three patients had two
metastatic sites (two patients
had liver and lung, and one
patient had liver and ovary) as
first sites (green line), whereas
the remaining 16 patients had
single sites (pulmonary or
lymph node metastases or
recurrent rectal cancer; yellow
line). The survival plot shows
time from Lt. c Time from
diagnosis of hepatic metastases
to death (purple line). The
orange line represents patients
who experienced pulmonary
metastases but no hepatic
relapse. From the diagnosis of
pulmonary metastases to the end
of follow-up, there were no
deaths in this group. d Overall
survival from time of
recurrence. The log-rank test
was used for calculation of p-
values in panels (b, c)
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hepatic and pulmonary resections, as many as 70 % had
hepatic first-site recurrences.11 Further, the prognosis after
first-site liver metastases described in literature is at the
same level as or slightly worse than that for pulmonary
metastases, whereas in our study the emergence of liver
metastases was seen only as part of disseminated disease and
was a devastating prognostic sign. The median time from
diagnosis of liver metastases to death was 14 months (range
4–21 months). This is in line with multiple-site recurrences
after liver resection of CLM reported from MSKCC, where
the median OS from the time of recurrence was 13 months
(range 11–16 months), compared with 24 months (range
17–30 months) in patients with single-site liver recur-
rences.6 All six patients who died in our study had hepatic
metastases, and six of the seven patients who experienced
hepatic metastases were dead at the end of follow-up.
Regarding metastatic spread of colorectal cancer, the
transplanted liver is situated downstream from the lung.
Following primary colorectal cancer, the portal flow dis-
tributes more than 90 % of the metastases to the liver,
whereas the incidence of lung metastases without liver
involvement is less than 10 % and appears from both colon
and rectal cancer.12 Metastases downstream of the lung
without lung involvement after primary colorectal cancer is
exceedingly rare.13 Further, metastases downstream of the
lung are associated with larger pulmonary tumors, and these
findings underscore the filtering function of the lungs.12
Downstream metastases such as skeletal metastases after
primary colorectal cancer are later events than lung metas-
tases and exhibit a poor prognosis. This provides a potential
explanation for why metastases to the transplanted liver were
seen only as part of disseminated disease and associated with
an adverse prognosis. Further, the unfortunate prognosis of
nonresectable hepatic metastases and hepatic recurrence in
new liver in contrast to the comparatively benign features of
pulmonary metastases underline the importance of hepatic
disease control for survival. This is in line with results after
locally directed modalities such as hepatic artery infusion
after conversion of nonresectable CLM to resection.14
The lack of first-site liver recurrence and the finding that
neohepatic metastases appeared only as part of dissemi-
nated disease suggest that there might be two distinct
mechanisms for hepatic recurrences after liver resection of
CLM. Metastases to the transplanted liver were of extra-
hepatic origin, whereas the liver-only first-site recurrences
that are seen most frequently in liver resection studies are,
at least partly, caused by residual tumor cells in the liver.
Although these cells have been lodged through portal flow
and developed through the metastatic cascade at an earlier
point, the current mechanism would probably be more
dependent on chemokines and other factors of homing.15–17
The overall number of patients who developed pulmon-
ary metastases in the study was extensive (n = 17). This is
probably due to vast hepatic tumor load, unfortunate char-
acteristics of the primary tumor, and the fact that 29 % of
patients had progressed on all standard lines of chemo-
therapy at Lt.10 Further, the time interval from Lt to initial
recurrence of lung metastases was short (the median time
was 4 months), and 62 % of the patients with lung-first
recurrence experienced recurrence within the first year. This
contrasts with findings after hepatic resection in which lung
recurrences appeared later. In one study, the median time
was 16 months, and in the MSKCC study, only 28 % of the
lung-first metastases recurred during the first year.4,6 In the
current study, most of the pulmonary metastases were slow
growing, and several were accessible to surgery. Patients
with pulmonary first-site recurrences had a 5-year OS of 72
% (95 % confidence interval 44–99 %). Further, no patient
with pulmonary metastases alone or in combination with
extrahepatic recurrences was deceased at the end of follow-
up. These are superior to results in CLM resection studies.
In a recent study, the 5-year OS was approximately 40 %
from the time of initial pulmonary recurrence after hepatic
resection for CLM.6 In addition, in our study, pulmonary
metastases were present at the time of Lt, or even before Lt
in seven patients. Our initial fear was accelerated growth of
overlooked metastases when patients were given the con-
tinuous immunosuppressive medication. However, six of
the seven patients who actually had pulmonary metastases
Time from when pulmonary metastases
   can be seen retrospectively on chest CT
Time for diagnosis of liver metastases
Time of death
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FIG. 3 Previous chest CT scans on 17 patients who experienced lung
metastases were reassessed. Tracing back from obvious metastatic
manifestations, prior metastatic nodules were found in several
patients. In seven patients they were present at or even before liver
transplantation. The plot shows the course of individual patients. Each
line is the time from the earliest manifestation of metastases seen
retrospectively on CT, the vertical line at point 0 is the time of liver
transplantation, and the red bar is the time of diagnosis of hepatic
metastases. The patients alive are in upper part of the plot, and the
dead, below
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at the time of Lt were among those who have survived
longest in the study. This pilot study cannot give possible
explanations for the slow growth rate of pulmonary
metastases. One can speculate whether the antineoplastic
properties of mammalian target of rapamycin inhibitors or
the removal of hepatic tumor load which would otherwise
have killed the patients and thus set the stage for more
slowly growing pulmonary metastases contributed to this
phenomenon. The standard chemotherapy given before Lt
may have suppressed the growth of manifest pulmonary
metastases preoperatively. Thus, the short disease-free
survival caused by increased growth of lung metastases
might be a consequence of termination of chemotherapy at
Lt. Nevertheless, a 5-year OS of 60 % demonstrates that the
immunosuppressive treatment used in the study did not
induce accelerated growth of pulmonary malignancy.
The finding of pulmonary metastases at the time of Lt and
previously by reexamination of CT scans illustrates limita-
tions in the preoperative screening procedure. Indeterminate
pulmonary nodules are quite common on pulmonary CT
studies. It is known from preoperative screening of CLM that
some nodules represent early metastases.18,19 In a recent
report from MSKCC, 43 % had subcentimeter pulmonary
nodules at the time of liver resection for CLM, and 35 % of
these were proven to be metastatic disease. There was a trend
toward shorter progression-free survival in patients with
subcentimeter pulmonary nodules compared with those
without.18 In this study, the nodules were small, uncharac-
teristic, and drawn attention to only retrospectively. Several
other small nodules of identical appearance present on the
CT examinations did not progress into metastases.
Conclusively, after Lt for nonresectable CLM, pul-
monary metastases appeared frequently and early but were
relatively indolent. This contrasts with the course of the
patients who developed hepatic metastases to the trans-
planted liver. These appeared exclusively as part of
disseminated disease, and there were no first-site liver-only
recurrences. The presence of lung metastases at the time of
Lt did not affect survival negatively.
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